{{Copy edit|for=[[WP:PUNCT|標點符號]]|date=2018年1月}}
{{Infobox cell
| Name        = T细胞
| Latin       = lymphocytus T
| Image       = Healthy Human T Cell.jpg
| Caption     = 人类T细胞的扫描电子显微镜图
| Width       = 
| Image2      = Red White Blood cells.jpg
| Caption2    = T淋巴细胞（右）（有异议）、[[血小板|血小板]]（中）和[[红细胞|红细胞]]（左）的扫描电子显微镜图片
| Precursor   = 
| System      = [[免疫系统|免疫系统]]
<!--
| Code = {{TerminologiaHistologica|2|00|04.1.02007}}
-->
}}
'''T细胞'''（{{lang-en|T cell}}、{{lang|en|T lymphocyte}}）是[[淋巴细胞|淋巴细胞]]的一种，在[[免疫反應|免疫反應]]中扮演着重要的角色。T是[[胸腺|胸腺]]（thymus）的[[英文|英文]][[缩写|缩写]]。T细胞在[[骨髓|骨髓]]被製造出來之後，在胸腺内進行「新兵訓練」分化成熟為不同亚型的效应T細胞，成熟后就移居于周围[[淋巴组织|淋巴组织]]中開始工作。

T细胞膜表面分子有两大类：[[T细胞受体|T细胞受体]]（TCR）和[[分化群|分化群]]分子（CD molecules），其与T细胞的功能相关，也是T细胞的[[表面标志|表面标志]]（cell-surface marker），可以用以分离、鉴定不同亚群的T细胞<ref>{{Cite book|edition=5th ed|chapter=|url=https://www.worldcat.org/oclc/45708106|publisher=Garland Pub|date=2001|location=New York|isbn=978-0-8153-3642-6|oclc=45708106|last=Janeway, Charles.|title=Immunobiology: the immune system in health and disease|first=|year=|pages=|access-date=2020-02-12|archive-date=2019-10-17|archive-url=https://web.archive.org/web/20191017142159/https://www.worldcat.org/title/immunobiology-5-the-immune-system-in-health-and-disease/oclc/45708106|dead-url=no}}</ref>。

== 发育 ==

=== 起源 ===
所有的T细胞都来源于[[造血干细胞|造血干细胞]]（HSC），造血干细胞之后会分化为[[多能祖细胞|多能祖细胞]]（MPP），多能祖细胞又会分化为共同淋巴祖细胞（CLP），CLP接下来只有三种分化路径，即T细胞、[[B细胞|B细胞]]和[[自然杀伤细胞|NK细胞]]<ref>{{Cite journal|title=One Niche to Rule Both Maintenance and Loss of Stemness in HSCs|url=https://www.ncbi.nlm.nih.gov/pubmed/28002722|last=Kondo|first=Motonari|date=2016-12-20|journal=Immunity|issue=6|doi=10.1016/j.immuni.2016.12.003|volume=45|pages=1177–1179|issn=1097-4180|pmid=28002722|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074731/https://www.ncbi.nlm.nih.gov/pubmed/28002722|dead-url=no}}</ref>。 那些分化为T细胞的CLP将会随着血流到达[[胸腺|胸腺]]，并成为早期胸腺祖细胞(ETP)，现在这些细胞既不表达[[CD4|CD4]]也不表达[[CD8受体|CD8]]<ref>{{Cite journal|title=Impaired CD8 T cell memory and CD4 T cell primary responses in IL-7R alpha mutant mice|url=https://www.ncbi.nlm.nih.gov/pubmed/17325202|last=Osborne|first=Lisa C.|last2=Dhanji|first2=Salim|date=2007-03-19|journal=The Journal of Experimental Medicine|issue=3|doi=10.1084/jem.20061871|volume=204|pages=619–631|issn=0022-1007|pmc=2137912|pmid=17325202|last3=Snow|first3=Jonathan W.|last4=Priatel|first4=John J.|last5=Ma|first5=Melissa C.|last6=Miners|first6=M. Jill|last7=Teh|first7=Hung-Sia|last8=Goldsmith|first8=Mark A.|last9=Abraham|first9=Ninan|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074735/https://www.ncbi.nlm.nih.gov/pubmed/17325202|dead-url=no}}</ref>。这些细胞将经过一轮[[细胞分裂|分裂]]，进入DN1阶段。

=== TCR-β选择 ===
在DN2阶段(CD44+CD25+)，细胞上调RAG1/2并重排[[T细胞受体|TCR（T细胞受体）]]-β[[基因座|基因座]]，[[V(D)J_重组|V-D-J序列]]和恒定区序列，目的是产生一个有功能的TCR-β链。当细胞经过DN3阶段(CD44-CD25+)时，细胞将会和TCRβ一起表达一个未经重排的α-链（pre-Tα），如果重排后的β-链可以和pre-Tα形成二聚体，细胞将产生信号停止β-链的重排<ref>{{Cite book|edition=8th ed|chapter=|url=https://www.worldcat.org/oclc/733935898|publisher=Garland Science|date=2012|location=New York|isbn=978-0-8153-4243-4|oclc=733935898|last=Murphy, Kenneth (Kenneth M.)|last2=Walport, Mark.|last3=Janeway, Charles.|title=Janeway's immunobiology|first=|year=|pages=pp. 301-305}}</ref>。虽然这个信号需要pre-TCR在[[细胞膜|细胞膜]]上表达，不过它与pre-TCR和[[配体|配体]]的结合无关。如果pre-TCR形成了，细胞会下调CD25并进入DN4阶段(CD25-CD44-)。这些细胞将继续分裂并重排TCRα的基因座。

=== 阳性选择 ===
双阳性(CD4+/CD8+)的T细胞会向胸腺皮层深处迁移，并会接触到胸腺皮层[[上皮细胞|上皮细胞]]表面的“自体抗原”（self-antigens）。这些自体抗原结合在胸腺上皮细胞表面的[[MHC|MHC分子]]上，只有与胸腺细胞的MHC分子表现出足够强的结合力的T细胞，才能接收到必要的“存活信号”，而无法接收到足够“存活信号”的T细胞将会[[凋亡|凋亡]]。在这个持续几天的阳性选择过程中，大部分的T细胞都会死去<ref>{{Cite journal|title=Positive and negative selection of T cells|url=https://www.ncbi.nlm.nih.gov/pubmed/12414722|last=Starr|first=Timothy K.|last2=Jameson|first2=Stephen C.|date=2003|journal=Annual Review of Immunology|doi=10.1146/annurev.immunol.21.120601.141107|volume=21|pages=139–176|issn=0732-0582|pmid=12414722|last3=Hogquist|first3=Kristin A.|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074746/https://www.ncbi.nlm.nih.gov/pubmed/12414722|dead-url=no}}</ref>。

一个T细胞的命运就在阳性选择的过程中被决定。在双阳性(CD4+/CD8+)T细胞中，能够与[[主要组织相容性复合体#第一类主要組織相容性複合體|MHC Ⅱ类分子]]结合得较好的将成为[[CD4+_T细胞|CD4+细胞]]，而和[[MHC_Ⅰ类分子|MHC Ⅰ类分子]]有更高亲和力的将成为[[CD8+细胞|CD8+细胞]]。将成为CD4+细胞的细胞将会逐渐下调自己的CD8，最终成为单阳性的CD4+细胞<ref>{{Cite journal|title=The MHC reactivity of the T cell repertoire prior to positive and negative selection|url=https://www.ncbi.nlm.nih.gov/pubmed/9054502|last=Zerrahn|first=J.|last2=Held|first2=W.|date=1997-03-07|journal=Cell|issue=5|doi=10.1016/s0092-8674(00)81905-4|volume=88|pages=627–636|issn=0092-8674|pmid=9054502|last3=Raulet|first3=D. H.|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074751/https://www.ncbi.nlm.nih.gov/pubmed/9054502|dead-url=no}}</ref>。

=== 阴性选择 ===
在阳性选择中存活下来的T细胞将会向胸腺皮质边缘和髓质区迁移；在髓质区，它们又会接触到胸腺髓质上皮细胞（mTECs）表面的自体抗原<ref>{{Cite journal|title=Autonomous role of medullary thymic epithelial cells in central CD4(+) T cell tolerance|url=https://www.ncbi.nlm.nih.gov/pubmed/20431619|last=Hinterberger|first=Maria|last2=Aichinger|first2=Martin|date=2010-06|journal=Nature Immunology|issue=6|doi=10.1038/ni.1874|volume=11|pages=512–519|issn=1529-2916|pmid=20431619|last3=Prazeres da Costa|first3=Olivia|last4=Voehringer|first4=David|last5=Hoffmann|first5=Reinhard|last6=Klein|first6=Ludger|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074757/https://www.ncbi.nlm.nih.gov/pubmed/20431619|dead-url=no}}</ref>。mTECs会在它们的[[MHC_Ⅰ类分子|MHC Ⅰ类分子]]上呈递来自全身各个组织的自体抗原。一些mTECs被胸腺[[樹狀細胞|树状细胞]]吞噬，它们的自体抗原就会呈递在树状细胞的[[MHC_Ⅱ类分子|MHC Ⅱ类分子]]上（经过了阳性选择的CD4+细胞只能识别MHC Ⅱ类分子）。在这里，与自体抗原表现出过强的亲和力的T细胞会接收到凋亡信号并凋亡（在这些细胞中也有一部分会成为[[调节T细胞|调节T细胞]]），存活下来的细胞就作为成熟的[[初级T细胞|初级T细胞]]离开胸腺<ref>{{Cite journal|title=Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2|url=https://www.ncbi.nlm.nih.gov/pubmed/28814669|last=Pekalski|first=Marcin L.|last2=García|first2=Arcadio Rubio|date=2017-08-17|journal=JCI insight|issue=16|doi=10.1172/jci.insight.93739|volume=2|issn=2379-3708|pmc=5621870|pmid=28814669|last3=Ferreira|first3=Ricardo C.|last4=Rainbow|first4=Daniel B.|last5=Smyth|first5=Deborah J.|last6=Mashar|first6=Meghavi|last7=Brady|first7=Jane|last8=Savinykh|first8=Natalia|last9=Dopico|first9=Xaquin Castro|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074801/https://www.ncbi.nlm.nih.gov/pubmed/28814669|dead-url=no}}</ref>。这一过程是中枢[[免疫耐受|免疫耐受]]的重要组成部分，其意义在于筛选掉可能对自体抗原产生反应的T细胞，从而避免[[自體免疫疾病|自体免疫疾病]]的发生。

=== 胸腺输出 ===
经过阳性选择和阴性选择，最初到达胸腺的T细胞中有98%死亡，存活下来的2%成为了具有成熟免疫功能的T细胞。胸腺产生成熟T细胞的数量大致随着个体衰老而减少，在中年人的体内，胸腺的大小平均每年缩小3%<ref>{{Cite journal|title=The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection|url=https://www.ncbi.nlm.nih.gov/pubmed/10837068|last=Haynes|first=B. F.|last2=Markert|first2=M. L.|date=2000|journal=Annual Review of Immunology|doi=10.1146/annurev.immunol.18.1.529|volume=18|pages=529–560|issn=0732-0582|pmid=10837068|last3=Sempowski|first3=G. D.|last4=Patel|first4=D. D.|last5=Hale|first5=L. P.|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074806/https://www.ncbi.nlm.nih.gov/pubmed/10837068|dead-url=no}}</ref>。所以，对中老年人而言，外周T细胞的增殖和再生对于免疫系统的意义更大。

== 分类 ==
T细胞根据功能的差异被分为几个亚型。虽然在胸腺中就[[分化|分化]]出了CD4+和CD8+两者，但是在外周Ｔ细胞还会发生进一步的分化。

=== 常规适应性T细胞 ===

====辅助性CD4+ T细胞====
[[辅助性T细胞|辅助性T细胞]]（T<sub>H</sub>细胞）对其他[[淋巴细胞|淋巴细胞]]的活动起辅助作用，包括[[B细胞|B细胞]]向[[浆细胞|浆细胞]]和[[记忆B细胞|记忆B细胞]]的发育，以及[[细胞毒性T细胞|细胞毒性T细胞]]和[[巨噬细胞|巨噬细胞]]的激活。它们也被称为CD4+ T细胞，因为它们的细胞表面有[[CD4|CD4]]蛋白的表达。辅助T细胞在遇到[[抗原呈递细胞|抗原呈递细胞]]（APC）表面MHC-II分子结合的外部[[抗原|抗原]]时被激活，一旦被激活就会快速分裂并开始分泌调节免疫反应的[[细胞因子|细胞因子]]。辅助T细胞在受到不同细胞因子刺激的情况下，也会进一步分化成不同亚型的辅助T细胞<ref>{{Cite journal|title=APC-derived cytokines and T cell polarization in autoimmune inflammation|url=https://www.ncbi.nlm.nih.gov/pubmed/17476341|last=Gutcher|first=Ilona|last2=Becher|first2=Burkhard|date=2007-05|journal=The Journal of Clinical Investigation|issue=5|doi=10.1172/JCI31720|volume=117|pages=1119–1127|issn=0021-9738|pmc=1857272|pmid=17476341|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074812/https://www.ncbi.nlm.nih.gov/pubmed/17476341|dead-url=no}}</ref>。它们是已知的[[人体免疫缺陷病毒|HIV病毒]]的目標细胞，在[[艾滋病|艾滋病]]发病时会急剧减少。

====調節性CD4+ T细胞====
[調節性T细胞]（T<sub>reg</sub>细胞）旧称抑制性T细胞，对于[[免疫耐受|免疫耐受]]至关重要。它们的主要工作就是及时有效的结束免疫反应，以及抑制那些从阴性筛选中逃逸的自体免疫T细胞，防止免疫反应对抑制性机体自身造成过度损害。

調節性T细胞既可以在[[胸腺|胸腺]]中发育分化完成，称为胸腺调节T细胞；也可以在外周组织受免疫反应诱导分化，称为外周调节T细胞<ref>{{Cite journal|title=Regulatory T cells: recommendations to simplify the nomenclature|url=https://www.ncbi.nlm.nih.gov/pubmed/23507634|last=Abbas|first=Abul K.|last2=Benoist|first2=Christophe|date=2013-04|journal=Nature Immunology|issue=4|doi=10.1038/ni.2554|volume=14|pages=307–308|issn=1529-2916|pmid=23507634|last3=Bluestone|first3=Jeffrey A.|last4=Campbell|first4=Daniel J.|last5=Ghosh|first5=Sankar|last6=Hori|first6=Shohei|last7=Jiang|first7=Shuiping|last8=Kuchroo|first8=Vijay K.|last9=Mathis|first9=Diane|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074816/https://www.ncbi.nlm.nih.gov/pubmed/23507634|dead-url=no}}</ref>。两者都表达[[FOXP3|FOXP3]]作为其细胞表面标志物，FOXP3基因的[[突变|突变]]会影响调节T细胞的发育，并诱发致命的自体免疫病[[IPEX症候群|IPEX]]。

其他几类不表达FOXP3基因的T细胞具有免疫抑制作用，例如Tr1细胞和Th3细胞。Tr1与IL-10相关，Th3与[[TGF-β|TGF-beta]]相关。最近，Th17细胞也被列入此类免疫抑制细胞之中<ref>{{Cite journal|title=Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells|url=https://www.ncbi.nlm.nih.gov/pubmed/24434314|last=Singh|first=Bhagirath|last2=Schwartz|first2=Jordan Ari|date=2013-11|journal=The Indian Journal of Medical Research|issue=5|volume=138|pages=591–594|issn=0971-5916|pmc=3928692|pmid=24434314|last3=Sandrock|first3=Christian|last4=Bellemore|first4=Stacey M.|last5=Nikoopour|first5=Enayat|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074822/https://www.ncbi.nlm.nih.gov/pubmed/24434314|dead-url=no}}</ref>。

==== 细胞毒性CD8+ T细胞 ====
[[细胞毒性T细胞|细胞毒性T细胞]](CTLs, killer T cells)负责杀伤被[[病毒|病毒]]感染的细胞和[[癌细胞|癌细胞]]，在对[[器官移植|器官移植]]的[[免疫排斥|免疫排斥]]中也有参与。其特点在于细胞表面的[[CD8|CD8]]蛋白质。它通过识别所有[[有核细胞|有核细胞]]表面的MHC-I分子上的[[肽|短肽]]抗原，来分辨正常细胞和应杀伤的异常细胞。细胞毒性T细胞还可分泌重要的细胞因子[[白细胞介素-2|IL-2]]和[[IFN-γ|IFNγ]]，来影响其他免疫细胞的功能，特别是[[巨噬细胞|巨噬细胞]]和[[NK细胞|NK细胞]]。

====记忆性T细胞====
还未结合过外部抗原的初级T细胞，一旦结合了抗原呈递细胞表面MHC分子所包裹的外部抗原，就会开始增殖分化为[[效应T细胞|效应T细胞]]和[[记忆T细胞|'''记忆T细胞''']]（其他信号适当的共刺激对这一过程也是必要的）。曾经，人们认为记忆T细胞只分为中央记忆T细胞和效应记忆T细胞<ref>{{Cite journal|title=Two subsets of memory T lymphocytes with distinct homing potentials and effector functions|url=https://www.ncbi.nlm.nih.gov/pubmed/10537110|last=Sallusto|first=F.|last2=Lenig|first2=D.|date=1999-10-14|journal=Nature|issue=6754|doi=10.1038/44385|volume=401|pages=708–712|issn=0028-0836|pmid=10537110|last3=Förster|first3=R.|last4=Lipp|first4=M.|last5=Lanzavecchia|first5=A.|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074827/https://www.ncbi.nlm.nih.gov/pubmed/10537110|dead-url=no}}</ref>。但是之后，新的记忆T细胞种类不断被发现，例如组织驻留记忆T细胞 (Trm)等等。记忆T细胞的共同特点在于其寿命较长（可長達數十年），而且在识别到特定抗原时可以快速分裂为大量的效应T细胞。通过这样的方式，记忆T细胞就为人体的[[免疫系统|免疫系统]]保存了对之前感染过[[病原体|病原体]]的“记忆”。记忆T既可以是CD4+也可以是CD8+，一般会表达[[CD45RO|CD45RO]]<ref>{{Cite journal|title=Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells|url=https://www.ncbi.nlm.nih.gov/pubmed/2965180|last=Akbar|first=A. N.|last2=Terry|first2=L.|date=1988-04-01|journal=Journal of Immunology (Baltimore, Md.: 1950)|issue=7|volume=140|pages=2171–2178|issn=0022-1767|pmid=2965180|last3=Timms|first3=A.|last4=Beverley|first4=P. C.|last5=Janossy|first5=G.|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074831/https://www.ncbi.nlm.nih.gov/pubmed/2965180|dead-url=no}}</ref>。

=== 类固有T细胞 ===

==== 自然杀伤T细胞 ====
[[自然殺傷T細胞|自然杀伤T细胞]](NKT细胞)，请不要把它和[[固有免疫|固有免疫]]中的[[自然杀伤细胞|自然杀伤细胞]]（NK细胞）混淆。 与一般T细胞识别MHC分子上的肽链抗原不同，NKT识别的是[[CD1d|CD1d]]分子上结合的[[糖蛋白|糖蛋白]]抗原。被激活后，它们可以执行类似辅助T细胞和细胞毒性T细胞的功能，即释放细胞因子和[[細胞毒素|细胞毒素]]。有证据表明，它们能够识别并杀灭某些肿瘤细胞和被[[疱疹病毒|疱疹病毒]]感染的细胞<ref>{{Cite journal|title=Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis|url=https://www.ncbi.nlm.nih.gov/pubmed/17353286|last=Mallevaey|first=Thierry|last2=Fontaine|first2=Josette|date=2007-05|journal=Infection and Immunity|issue=5|doi=10.1128/IAI.01178-06|volume=75|pages=2171–2180|issn=0019-9567|pmc=1865739|pmid=17353286|last3=Breuilh|first3=Laetitia|last4=Paget|first4=Christophe|last5=Castro-Keller|first5=Alexandre|last6=Vendeville|first6=Catherine|last7=Capron|first7=Monique|last8=Leite-de-Moraes|first8=Maria|last9=Trottein|first9=François|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074835/https://www.ncbi.nlm.nih.gov/pubmed/17353286|dead-url=no}}</ref>。

==== 粘膜相关的不变T细胞 ====
[[粘膜相关的不变T细胞|粘膜相关的不变T细胞]]（MAIT）具有固有免疫效应细胞的特质<ref name=":02">{{cite journal|title=The Role of Mucosal Associated Invariant T Cells in Antimicrobial Immunity|date=2015-07-06|journal=Frontiers in Immunology|doi=10.3389/fimmu.2015.00344|volume=6|pages=344|pmc=4492155|pmid=26217338|vauthors=Napier RJ, Adams EJ, Gold MC, Lewinsohn DM}}</ref><ref>{{cite journal|title=Mucosal associated invariant T cells and the immune response to infection|date=August 2011|journal=Microbes and Infection|issue=8–9|doi=10.1016/j.micinf.2011.03.007|volume=13|pages=742–8|pmc=3130845|pmid=21458588|vauthors=Gold MC, Lewinsohn DM}}</ref>。在人体内，MAIT细胞分布于[[血液|血液]]、[[肝脏|肝脏]]、[[肺部|肺部]]、[[黏膜|黏膜]]，具有抵御[[微生物|微生物]]感染的能力<ref name=":02" />。MHC-I的类似物，MR1，可以向MAIT细胞呈递[[细菌|细菌]]产生的代谢物抗原<ref name=":4">{{cite journal|title=Recognition of Vitamin B Precursors and Byproducts by Mucosal Associated Invariant T Cells|date=December 2015|journal=The Journal of Biological Chemistry|issue=51|doi=10.1074/jbc.R115.685990|volume=290|pages=30204–11|pmc=4683245|pmid=26468291|vauthors=Eckle SB, Corbett AJ, Keller AN, Chen Z, Godfrey DI, Liu L, Mak JY, Fairlie DP, Rossjohn J, McCluskey J}}</ref><ref name=":6">{{cite journal|title=Mucosal-associated invariant T-cells: new players in anti-bacterial immunity|date=2014-10-08|journal=Frontiers in Immunology|doi=10.3389/fimmu.2014.00450|volume=5|pages=450|pmc=4189401|pmid=25339949|vauthors=Ussher JE, Klenerman P, Willberg CB}}</ref><ref name=":12">{{cite journal|title=MR1-Restricted Mucosal-Associated Invariant T Cells and Their Activation during Infectious Diseases|date=2015-06-16|journal=Frontiers in Immunology|doi=10.3389/fimmu.2015.00303|volume=6|pages=303|pmc=4468870|pmid=26136743|vauthors=Howson LJ, Salio M, Cerundolo V}}</ref>。接受了MR1呈递的外部抗原后，MAIT细胞可以释放促[[炎症|炎症]][[细胞因子|细胞因子]]并裂解被细菌感染的细胞<ref name=":02" /><ref name=":12" />。MAIT也可以通过不依靠MR1的信号通路激活<ref name=":12" />。除了表现出类似[[固有免疫|固有免疫]]的功能外，MAIT细胞也辅助[[获得性免疫|获得性免疫]]反应，甚至表现出类似[[记忆细胞|记忆细胞]]的特征<ref name=":02" />。此外，MAIT也被认为在[[自體免疫性疾病|自体免疫病]]中发挥作用，如[[多发性硬化症|多发性硬化]]、[[风湿|风湿]]和[[炎症性肠病|炎症性肠病]]<ref name=":5">{{cite journal|title=Mucosal-associated invariant T cells in autoimmunity, immune-mediated diseases and airways disease|date=May 2016|journal=Immunology|issue=1|doi=10.1111/imm.12582|volume=148|pages=1–12|pmc=4819138|pmid=26778581|vauthors=Hinks TS}}</ref><ref name=":9">{{cite journal|title=Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis|date=March 2017|journal=Immunology Letters|doi=10.1016/j.imlet.2017.01.009|volume=183|pages=1–7|pmid=28119072|vauthors=Bianchini E, De Biasi S, Simone AM, Ferraro D, Sola P, Cossarizza A, Pinti M}}</ref>，虽然决定性的证据还有待发现<ref>{{cite journal|title=Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases|date=May 2014|journal=Clinical and Experimental Immunology|issue=2|doi=10.1111/cei.12277|volume=176|pages=266–74|pmc=3992039|pmid=24450998|vauthors=Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, Chatelain D, Barre A, Nguyen-Khac E, Lantz O, Dupas JL, Treiner E}}</ref><ref>{{cite journal|title=MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution|date=May 2009|journal=Proceedings of the National Academy of Sciences of the United States of America|issue=20|doi=10.1073/pnas.0903196106|volume=106|pages=8290–5|bibcode=2009PNAS..106.8290H|pmc=2688861|pmid=19416870|vauthors=Huang S, Martin E, Kim S, Yu L, Soudais C, Fremont DH, Lantz O, Hansen TH}}</ref><ref>{{cite journal|title=Bacteria, mucosal-associated invariant T cells and MR1|date=November 2010|journal=Immunology and Cell Biology|issue=8|doi=10.1038/icb.2010.104|volume=88|pages=767–9|pmid=20733595|vauthors=Chua WJ, Hansen TH}}</ref><ref>{{cite journal|title=MR1 presents microbial vitamin B metabolites to MAIT cells|url=https://espace.library.uq.edu.au/view/UQ:284808/UQ284808_OA.pdf|date=November 2012|journal=Nature|issue=7426|doi=10.1038/nature11605|volume=491|pages=717–23|bibcode=2012Natur.491..717K|pmid=23051753|vauthors=Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O'Hair RA, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, McCluskey J}}</ref>。

==== γδ T细胞 ====
[[γδ_T细胞|γδ T细胞]]代表了T细胞中一小部分不表达αβ-[[T细胞受体|TCR]]而表达γδ-TCR的类型，在[[小鼠|小鼠]]和人体内仅占全部T细胞的2%；在兔子、绵羊和鸡体内，γδ T细胞占全部T细胞的比例则可能高达60%。它们主要分布在[[腸道|肠道]]粘膜，作为一类上皮内淋巴细胞。关于其抗原识别的细节我们仍知之甚少，不过似乎γδ T细胞并不受限于MHC分子的呈递。特别的是，γδ T细胞能够对一类[[磷酸类抗原|磷酸类抗原]]做出快速的反应，而这类抗原物质在各种细胞（细菌、植物、癌细胞等）中都有发现。

== 活化 ==
[[File:T_cell_activation.svg|右]] resource booklet [https://www.niaid.nih.gov/publications/immune/the_immune_system.pdf "Understanding the Immune System (pdf)"] {{Wayback|url=https://www.niaid.nih.gov/publications/immune/the_immune_system.pdf |date=20070103005411 }}.</ref>]]
[[CD4+_T细胞|CD4+ T细胞]]的激活需要T细胞上的[[TCR|TCR]]和共受体（[[CD28|CD28]]或[[ICOS|ICOS]]），[[抗原呈递细胞|抗原呈递细胞]]上的MHCII和[[共激活分子|共激活分子]]两对分子的分别，同时结合。仅其中一对的结合，无法产生有效的T细胞激活。理想的[[CD8+_T细胞|CD8+ T细胞]]激活则依赖于CD4+  T细胞的信号转导<ref>{{Cite journal|title=Effector and memory CTL differentiation|url=https://www.ncbi.nlm.nih.gov/pubmed/17129182|last=Williams|first=Matthew A.|last2=Bevan|first2=Michael J.|date=2007|journal=Annual Review of Immunology|doi=10.1146/annurev.immunol.25.022106.141548|volume=25|pages=171–192|issn=0732-0582|pmid=17129182|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074850/https://www.ncbi.nlm.nih.gov/pubmed/17129182|dead-url=no}}</ref>。CD4+细胞可以在初级CD8 T细胞的初次免疫应答中给予帮助，并且在急性[[感染|感染]]的后期维持CD8+ 记忆T细胞的活性。所以，CD4+ T的激活对于CD8+ T细胞的活动是有利的<ref>{{cite journal|title=CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes|date=February 2003|journal=Nature|issue=6925|doi=10.1038/nature01441|volume=421|pages=852–6|bibcode=2003Natur.421..852J|pmid=12594515|vauthors=Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP}}</ref><ref>{{cite journal|title=Requirement for CD4 T cell help in generating functional CD8 T cell memory|date=April 2003|journal=Science|issue=5617|doi=10.1126/science.1082305|volume=300|pages=337–9|bibcode=2003Sci...300..337S|pmid=12690201|vauthors=Shedlock DJ, Shen H}}</ref><ref>{{cite journal|title=CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection|date=September 2004|journal=Nature Immunology|issue=9|doi=10.1038/ni1105|volume=5|pages=927–33|pmc=2776074|pmid=15300249|vauthors=Sun JC, Williams MA, Bevan MJ}}</ref>。

相比于MHC分子上的抗原，抗原呈递细胞的共激活分子一般是由病原体的副产物、[[热休克蛋白|热休克蛋白]]或者[[壞死|坏死]]的细胞碎片诱导表达的。共刺激机制被认为可以避免[[自体免疫|自体免疫]]的发生，因为即使T细胞错误地结合了自体抗原，也可能因为没有受到合适的共刺激而无法正常活化。一旦T细胞被正确地活化，它的细胞表面蛋白表达就会发生巨大的改变，活化T细胞的标志蛋白包括[[CD69|CD69]]，[[CD71|CD71]]，[[CD25|CD25]] (也是[[调节T细胞|调节T细胞]]的标志)和[[HLA|HLA-DR]] (人类T细胞的特异标志)。CTLA-4在活化T细胞表面的上调，对共激活受体有竞争性抑制作用，可以避免活化T细胞的过度活化。活化T细胞的表面[[糖基化|糖基化]]情况也有改变<ref>{{cite journal|title=Glycans in the immune system and The Altered Glycan Theory of Autoimmunity|journal=J Autoimmun|issue=6|doi=10.1016/j.jaut.2014.12.002|year=2015|volume=57|pages=1–13|pmc=4340844|pmid=25578468|vauthors=Maverakis E, Kim K, Shimoda M, Gershwin M, Patel F, Wilken R, Raychaudhuri S, Ruhaak LR, Lebrilla CB}}</ref>。

[[T细胞受体|T细胞受体]]（TCR）是由几种[[蛋白质|蛋白质]]组合成的复合体。TCR的两个主要组分是由两个独立[[基因|基因]]分别编码的TCRα和TCRβ，其他的组分包括CD3家族的蛋白：CD3εγ和CD3εδ的异二聚体，以及最重要的CD3ζ同二聚体。CD3ζ同二聚体上共有6个ITAM基序，可被[[磷酸化|磷酸化]]并启动一系列级联反应，导致TCR复合体的聚集。

虽然在绝大部分情况下T细胞活化都依赖于TCR对抗原的识别，其他的活化途径也有被发现，例如[[细胞毒性T细胞|细胞毒性T细胞]]可以被其他CD8 T细胞识别并导致自身的极化<ref name="pmid21045195">{{cite journal|title=CTLs respond with activation and granule secretion when serving as targets for T cell recognition|date=January 2011|journal=Blood|issue=3|doi=10.1182/blood-2010-05-283770|volume=117|pages=1042–52|pmc=3035066|pmid=21045195|vauthors=Milstein O, Hagin D, Lask A, Reich-Zeliger S, Shezen E, Ophir E, Eidelstein Y, Afik R, Antebi YE, Dustin ML, Reisner Y}}</ref>。T细胞活化的过程也受到[[活性氧类|活性氧类]]物质的影响<ref>{{cite journal|title=T cells and reactive oxygen species|date=October 2015|journal=Journal of Biomedical Science|doi=10.1186/s12929-015-0194-3|volume=22|pages=85|pmc=4608155|pmid=26471060|vauthors=Belikov AV, Schraven B, Simeoni L}}</ref>。

=== 抗原识别 ===
T细胞的主要特点就是能够分辨正常细胞和异常细胞的能力<ref name="Feinerman_2008">{{cite journal|title=Quantitative challenges in understanding ligand discrimination by alphabeta T cells|journal=Mol. Immunol.|issue=3|doi=10.1016/j.molimm.2007.03.028|year=2008|volume=45|pages=619–31|pmc=2131735|pmid=17825415|vauthors=Feinerman O, Germain RN, Altan-Bonnet G}}</ref>。不论是正常细胞还是异常细胞，都会表达大量的[[主要组织相容性复合体|MHC]]-抗原多肽复合体（pMHC）。虽然T细胞与正常细胞的pMHC有一定结合力，但是T细胞并不会被激活；但即使异常细胞的pMHC与正常细胞只有细微的差别，也能够刺激T细胞发生免疫反应。这样对不同抗原完全不同的反应特征称为T细胞的'''抗原识别'''，关于这一机理实现的具体细节如今仍然没有定论<ref name="pmid24636916">{{cite journal|title=An induced rebinding model of antigen discrimination|journal=Trends Immunol.|issue=4|doi=10.1016/j.it.2014.02.002|year=2014|volume=35|pages=153–8|pmc=3989030|pmid=24636916|vauthors=Dushek O, van der Merwe PA}}</ref>。

== 临床意义 ==

=== 缺陷 ===
'''T细胞缺陷'''可能意味着T细胞数量的减少或者T细胞功能的缺失。完全的T细胞缺陷可能来自于一些遗传因素，例如[[嚴重複合型免疫缺乏症|严重复合型免疫缺乏症]](SCID)、[[欧门氏症候群|欧门氏症候群]]或[[软骨毛发发育不全|软骨毛发发育不全]]。[46]部分的T细胞缺陷可能是由于[[获得性免疫缺陷综合征|获得性免疫缺陷综合征]](AIDS)、遗传性的[[迪喬治症候群|迪乔治综合征]](DGS)、[[染色体断裂综合征|染色体断裂综合征]](CBSs)，或者[[B细胞|B细胞]]和T细胞的复合缺陷，例如[[共济失调微血管扩张症候群|毛细血管扩张性运动失调]] (AT) 和欧德里综合征（{{Translink|en|Wiskott–Aldrich syndrome}}）<ref name="Schwartz2011">[http://emedicine.medscape.com/article/888372-overview Medscape >  T-cell Disorders] {{Wayback|url=http://emedicine.medscape.com/article/888372-overview |date=20191230120104 }}.  Author: Robert A Schwartz, MD, MPH; Chief Editor: Harumi Jyonouchi, MD.  Updated: May 16, 2011</ref>。

T细胞缺陷患者面临的主要风险，主要是一些细胞内病原体，例如[[单纯疱疹病毒|单纯疱疹病毒]]、[[分枝杆菌|分枝杆菌]]和[[李斯特菌|李斯特菌]]。同时，[[真菌感染|真菌感染]]在T细胞缺陷患者身上往往也很常见且严重<ref>{{Cite book|edition=3rd ed|chapter=|url=https://www.worldcat.org/oclc/592756309|publisher=Blackwell Pub|date=2006|location=Malden, Mass.|isbn=978-1-4443-2393-1|oclc=592756309|last=Bannister, Barbara A.|last2=Jones, Jane.|last3=|title=Infection : microbiology and management|first=|year=|pages=435}}</ref>。

=== 癌症 ===
{{Main|T细胞淋巴瘤}}
T细胞[[癌变|癌变]]诱发的肿瘤称为[[T细胞淋巴瘤|T细胞淋巴瘤]]，在[[非霍奇金淋巴瘤|非霍奇金淋巴瘤]]中约占10%<ref name="The Lymphomas">{{cite web|title=The Lymphomas|url=http://www.leukemia-lymphoma.org/attachments/National/br_1161891669.pdf|accessdate=2008-04-07|date=May 2006|publisher=The Leukemia & Lymphoma Society|archiveurl=https://web.archive.org/web/20080706143003/http://www.leukemia-lymphoma.org/attachments/National/br_1161891669.pdf|archivedate=2008-07-06|page=2|url-status=dead|dead-url=no}}</ref>。

=== 耗竭 ===
'''T细胞耗竭'''是一种T细胞功能失常的状态，其表现为进展性的功能丧失、[[基因表达谱|基因表达谱]]的变化、和抑制性[[细胞因子|细胞因子]]的持续分泌。T细胞耗竭可能发生于慢性感染、[[敗血症|败血症]]、[[癌症|癌症]]的进程中<ref>{{Cite journal|title=T-cell exhaustion: characteristics, causes and conversion|url=https://www.ncbi.nlm.nih.gov/pubmed/20201977|last=Yi|first=John S.|last2=Cox|first2=Maureen A.|date=2010-04|journal=Immunology|issue=4|doi=10.1111/j.1365-2567.2010.03255.x|volume=129|pages=474–481|issn=1365-2567|pmc=2842494|pmid=20201977|last3=Zajac|first3=Allan J.|access-date=2020-02-23|archive-date=2020-03-26|archive-url=https://web.archive.org/web/20200326095150/https://www.ncbi.nlm.nih.gov/pubmed/20201977|dead-url=no}}</ref>。耗竭的T细胞即使再次暴露于[[抗原|抗原]]刺激之中也无法恢复正常功能<ref>{{Cite journal|title=Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment|url=https://www.ncbi.nlm.nih.gov/pubmed/29483916|last=Wang|first=Qin|last2=Pan|first2=Wen|date=2018|journal=Frontiers in Immunology|doi=10.3389/fimmu.2018.00219|volume=9|pages=219|issn=1664-3224|pmc=5816053|pmid=29483916|last3=Liu|first3=Yanan|last4=Luo|first4=Jinzhuo|last5=Zhu|first5=Dan|last6=Lu|first6=Yinping|last7=Feng|first7=Xuemei|last8=Yang|first8=Xuecheng|last9=Dittmer|first9=Ulf|access-date=2020-02-23|archive-date=2020-03-26|archive-url=https://web.archive.org/web/20200326095154/https://www.ncbi.nlm.nih.gov/pubmed/29483916|dead-url=no}}</ref>。

==== 慢性感染和败血症 ====
T细胞耗竭的直接原因包括持续的抗原刺激、以及[[CD4+_T细胞|CD4细胞]]的缺失<ref>{{Cite journal|title=CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection|url=https://www.ncbi.nlm.nih.gov/pubmed/7966595|last=Matloubian|first=M.|last2=Concepcion|first2=R. J.|date=1994-12|journal=Journal of Virology|issue=12|volume=68|pages=8056–8063|issn=0022-538X|pmc=PMC237269|pmid=7966595|last3=Ahmed|first3=R.|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074921/https://www.ncbi.nlm.nih.gov/pubmed/7966595|dead-url=no}}</ref>。长时间的抗原暴露和高[[病毒|病毒]]负载可以加重T细胞耗竭的程度。2-4周的持续抗原暴露就可导致T细胞耗竭<ref>{{Cite journal|title=Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection|url=https://www.ncbi.nlm.nih.gov/pubmed/22623779|last=Angelosanto|first=Jill M.|last2=Blackburn|first2=Shawn D.|date=2012-08|journal=Journal of Virology|issue=15|doi=10.1128/JVI.00889-12|volume=86|pages=8161–8170|issn=1098-5514|pmc=3421680|pmid=22623779|last3=Crawford|first3=Alison|last4=Wherry|first4=E. John|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074926/https://www.ncbi.nlm.nih.gov/pubmed/22623779|dead-url=no}}</ref>。另一个可以导致T细胞耗竭的因素是包括[[PD-1配体1|PD-1]]在内的一系列抑制性受体<ref>{{cite journal|title=T cell exhaustion|date=June 2011|journal=Nature Immunology|issue=6|doi=10.1038/ni.2035|volume=12|pages=492–9|pmid=21739672|vauthors=Wherry EJ}}</ref><ref>{{cite journal|title=+ T cells during bovine leukemia virus infection|date=June 2018|journal=Veterinary Research|issue=1|doi=10.1186/s13567-018-0543-9|volume=49|pages=50|language=En|pmc=6006750|pmid=29914540|vauthors=Okagawa T, Konnai S, Nishimori A, Maekawa N, Goto S, Ikebuchi R, Kohara J, Suzuki Y, Yamada S, Kato Y, Murata S, Ohashi K}}</ref>。细胞因子[[白介素|IL-10]]或[[TGF-β|TGF-β]]也可以导致耗竭<ref>{{cite journal|title=Interleukin-10 determines viral clearance or persistence in vivo|date=November 2006|journal=Nature Medicine|issue=11|doi=10.1038/nm1492|volume=12|pages=1301–9|pmc=2535582|pmid=17041596|vauthors=Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB}}</ref><ref>{{cite journal|title=Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo|date=July 2009|journal=Immunity|issue=1|doi=10.1016/j.immuni.2009.06.015|volume=31|pages=145–57|pmc=3039716|pmid=19604493|vauthors=Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI}}</ref>。[[调节T细胞|调节T细胞]]因为可以分泌IL-10和TGF-β，也与T细胞耗竭相关<ref>{{cite journal|title=Role of regulatory T cells during virus infection|date=September 2013|journal=Immunological Reviews|issue=1|doi=10.1111/imr.12085|volume=255|pages=182–96|pmc=3748387|pmid=23947355|vauthors=Veiga-Parga T, Sehrawat S, Rouse BT}}</ref>。在阻断PD-1受体并减少调节T细胞数量后，T细胞耗竭的情况可以得到反转<ref>{{cite journal|title=Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection|date=August 2014|journal=The Journal of Experimental Medicine|issue=9|doi=10.1084/jem.20132577|volume=211|pages=1905–18|pmc=4144726|pmid=25113973|vauthors=Penaloza-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, West EE, O'Mara L, Yang S, Konieczny BT, Sharpe AH, Freeman GJ, Rudensky AY, Ahmed R}}</ref>。[58]在败血症中，抑制性的[[细胞因子风暴|细胞因子风暴]]也会造成T细胞耗竭<ref>{{cite journal|title=The late phase of sepsis is characterized by an increased microbiological burden and death rate|date=July 2011|journal=Critical Care|issue=4|doi=10.1186/cc10332|volume=15|pages=R183|language=En|pmc=3387626|pmid=21798063|vauthors=Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, Bauer M, Riedemann NC}}</ref><ref name="Boomer JS 2011">{{cite journal|title=Immunosuppression in patients who die of sepsis and multiple organ failure|date=December 2011|journal=JAMA|issue=23|doi=10.1001/jama.2011.1829|volume=306|pages=2594–605|pmc=3361243|pmid=22187279|vauthors=Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS}}</ref>。现在已有致力于通过阻断抑制性受体的方式来治疗败血症的疗法研究<ref>{{cite journal|title=Anti-PD-L1 peptide improves survival in sepsis|date=February 2017|journal=The Journal of Surgical Research|doi=10.1016/j.jss.2016.08.099|volume=208|pages=33–39|pmc=5535083|pmid=27993215|vauthors=Shindo Y, McDonough JS, Chang KC, Ramachandra M, Sasikumar PG, Hotchkiss RS}}</ref><ref>{{cite journal|title=Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1|date=December 2016|journal=Journal of Leukocyte Biology|issue=6|doi=10.1189/jlb.4hi0616-255r|volume=100|pages=1239–1254|pmc=5110001|pmid=27671246|vauthors=Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS}}</ref><ref name="pmid29689313">{{cite journal|title=Alpha-lactose reverses liver injury via blockade of Tim-3-mediated CD8 apoptosis in sepsis|date=July 2018|journal=Clinical Immunology|issue=|doi=10.1016/j.clim.2018.04.010|volume=192|pages=78–84|pmid=29689313|vauthors=Wei Z, Li P, Yao Y, Deng H, Yi S, Zhang C, Wu H, Xie X, Xia M, He R, Yang XP, Tang ZH}}</ref>。

==== 器官移植 ====
与感染时的情况类似，[[器官移植|器官移植]]带来的持续异种抗原暴露也会造成T细胞耗竭<ref>{{cite journal|title=The role of peripheral T-cell deletion in transplantation tolerance|date=May 2001|journal=Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|issue=1409|doi=10.1098/rstb.2001.0845|volume=356|pages=617–23|pmc=1088449|pmid=11375065|vauthors=Wells AD, Li XC, Strom TB, Turka LA}}</ref>。[[肾|肾]]移植后，T细胞应答能力会随时间减弱<ref>{{cite journal|title=Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients|date=July 2015|journal=Journal of the American Society of Nephrology|issue=7|doi=10.1681/ASN.2014060588|volume=26|pages=1711–20|pmc=4483591|pmid=25377077|vauthors=Halloran PF, Chang J, Famulski K, Hidalgo LG, Salazar ID, Merino Lopez M, Matas A, Picton M, de Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J}}</ref>。这些数据说明T细胞耗竭导致的CD8+ T细胞数量减少可能是器官移植耐受中的重要一环<ref>{{cite journal|title=Exhaustive differentiation of alloreactive CD8+ T cells: critical for determination of graft acceptance or rejection|url=http://pure-oai.bham.ac.uk/ws/files/9323851/0108BM3Tx.pdf|date=May 2008|journal=Transplantation|issue=9|doi=10.1097/TP.0b013e31816dd64a|volume=85|pages=1339–47|pmid=18475193|vauthors=Steger U, Denecke C, Sawitzki B, Karim M, Jones ND, Wood KJ|access-date=2020-02-23|archive-date=2020-02-23|archive-url=https://web.archive.org/web/20200223055206/http://pure-oai.bham.ac.uk/ws/files/9323851/0108BM3Tx.pdf|dead-url=no}}</ref>。已有几项研究证明了慢性感染对器官移植后的免疫耐受和长期生存有利，而T细胞耗竭起着一定介导的作用<ref>{{cite journal|title=Cytomegalovirus-Induced Expression of CD244 after Liver Transplantation Is Associated with CD8+ T Cell Hyporesponsiveness to Alloantigen|date=August 2015|journal=Journal of Immunology|issue=4|doi=10.4049/jimmunol.1500440|volume=195|pages=1838–48|pmid=26170387|vauthors=de Mare-Bredemeijer EL, Shi XL, Mancham S, van Gent R, van der Heide-Mulder M, de Boer R, Heemskerk MH, de Jonge J, van der Laan LJ, Metselaar HJ, Kwekkeboom J}}</ref><ref>{{cite journal|title=IL-10 Induces T Cell Exhaustion During Transplantation of Virus Infected Hearts|date=2016|journal=Cellular Physiology and Biochemistry|issue=3|doi=10.1159/000443067|volume=38|pages=1171–81|language=en|pmid=26963287|vauthors=Gassa A, Jian F, Kalkavan H, Duhan V, Honke N, Shaabani N, Friedrich SK, Dolff S, Wahlers T, Kribben A, Hardt C, Lang PA, Witzke O, Lang KS}}</ref><ref>{{cite journal|title=CMV Primary Infection Is Associated With Donor-Specific T Cell Hyporesponsiveness and Fewer Late Acute Rejections After Liver Transplantation|date=September 2015|journal=American Journal of Transplantation|issue=9|doi=10.1111/ajt.13288|volume=15|pages=2431–42|pmid=25943855|vauthors=Shi XL, de Mare-Bredemeijer EL, Tapirdamaz Ö, Hansen BE, van Gent R, van Campenhout MJ, Mancham S, Litjens NH, Betjes MG, van der Eijk AA, Xia Q, van der Laan LJ, de Jonge J, Metselaar HJ, Kwekkeboom J}}</ref>。虽然已有T细胞耗竭对器官移植有利的证据，但是T细胞耗竭同时带来的感染和癌变风险依然不能忽视<ref>{{cite journal|title=Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape|date=February 2012|journal=Cancer Research|issue=4|doi=10.1158/0008-5472.CAN-11-1620|volume=72|pages=917–27|pmc=3288154|pmid=22186141|vauthors=Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA}}</ref>。

==== 癌症 ====
在癌症进程中，T细胞耗竭显然对癌组织的存活有利。已有研究证明癌细胞和一些癌症相关细胞可以主动地诱导T细胞耗竭的发生<ref>{{cite journal|title=T cells in multiple myeloma display features of exhaustion and senescence at the tumor site|date=November 2016|journal=Journal of Hematology & Oncology|issue=1|doi=10.1186/s13045-016-0345-3|volume=9|pages=116|language=En|pmc=5093947|pmid=27809856|vauthors=Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, Jöhrer K}}</ref><ref>{{cite journal|title=+ T Cells to protect tumour cells|date=March 2018|journal=Nature Communications|issue=1|doi=10.1038/s41467-018-03347-0|volume=9|pages=948|pmc=5838096|pmid=29507342|vauthors=Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD}}</ref> <ref>{{Cite journal|title=The ion channel network in T lymphocytes, a target for immunotherapy|url=https://linkinghub.elsevier.com/retrieve/pii/S152166161100338X|last=Conforti|first=Laura|date=2012-02-10|journal=Clinical Immunology|issue=2|doi=10.1016/j.clim.2011.11.009|volume=142|pages=105–106|language=en|via=|access-date=2020-02-23|archive-date=2020-03-18|archive-url=https://web.archive.org/web/20200318074937/https://linkinghub.elsevier.com/retrieve/pii/S152166161100338X|dead-url=no}}</ref>。在[[白血病|白血病]]中，T细胞耗竭也与其复发相关<ref>{{cite journal|title=T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation|date=May 2018|journal=Clinical Immunology|doi=10.1016/j.clim.2018.02.009|volume=190|pages=32–40|pmid=29477343|vauthors=Liu L, Chang YJ, Xu LP, Zhang XH, Wang Y, Liu KY, Huang XJ}}</ref>。一些研究甚至提出可以基于T细胞抑制性受体PD-1的表达状态来预测白血病复发的情况<ref>{{cite journal|title=PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation|date=July 2015|journal=Blood Cancer Journal|issue=7|doi=10.1038/bcj.2015.58|volume=5|pages=e330|language=En|pmc=4526784|pmid=26230954|vauthors=Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H}}</ref>。由于免疫抑制性受体与T细胞耗竭以及癌症之间的关系，近年来有大量的研究和临床试验致力于通过阻断免疫抑制性受体来治疗癌症，其中有一些已经被认定有效并投入[[PD-1/PD-L1抑制剂|临床使用]]<ref>{{Cite news|url=https://medi-paper.com/us-fda-approved-immune-checkpoint-inhibitors-approved-immunotherapies/|title=U.S. FDA Approved Immune-Checkpoint Inhibitors and Immunotherapies|date=2018-08-21|work=Medical Writer Agency {{!}} 香港醫學作家 {{!}} MediPR {{!}} MediPaper Hong Kong|access-date=2018-09-22|language=en-GB|archive-date=2018-09-04|archive-url=https://web.archive.org/web/20180904082113/https://medi-paper.com/us-fda-approved-immune-checkpoint-inhibitors-approved-immunotherapies/|dead-url=no}}</ref><ref>{{cite journal|title=Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade|date=May 2011|journal=Proceedings of the National Academy of Sciences of the United States of America|issue=22|doi=10.1073/pnas.1015298108|volume=108|pages=9196–201|pmc=3107287|pmid=21576466|vauthors=Bhadra R, Gigley JP, Weiss LM, Khan IA}}</ref>。

== 参见 ==
* [[白细胞|白细胞]]
*[[B细胞|B细胞]]
*[[嵌合抗原受體T細胞|嵌合抗原受体T细胞]]

== 参考文献 ==
{{Reflist|30em}}

==外部連結==
* [http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&rid=imm.TOC&depth=2 Immunobiology, 5th Edition]{{Wayback|url=http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&rid=imm.TOC&depth=2 |date=20090910090537 }}
* [https://web.archive.org/web/20070103005411/http://www.niaid.nih.gov/Publications/immune/the_immune_system.pdf niaid.nih.gov] – The Immune System
* [https://web.archive.org/web/20181211160636/http://www.tcells.org/ T-cell Group – Cardiff University]
* [http://content.nejm.org/cgi/content/full/358/25/2698 (Successful!) Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1]{{Wayback|url=http://content.nejm.org/cgi/content/full/358/25/2698 |date=20100105070457 }}.
* [http://www.modelingimmunity.org The Center for Modeling Immunity to Enteric Pathogens (MIEP)]{{Wayback|url=http://www.modelingimmunity.org/ |date=20181011184340 }}
* {{cite journal|url=http://linkinghub.elsevier.com/retrieve/pii/0167569993902168|pages=137–140|title=The tale of T cells|journal=Immunology Today|volume=14|issue=3|accessdate=2018-04-02|doi=10.1016/0167-5699(93)90216-8|author=Anthony J. Davies|archive-date=2018-06-29|archive-url=https://web.archive.org/web/20180629152114/https://linkinghub.elsevier.com/retrieve/pii/0167569993902168|dead-url=no}}
{{-}}
{{血液}}
{{淋巴细胞}}
{{免疫系統}}
{{淋巴组织解剖学}}
{{過敏及自體免疫疾病}}

[[Category:T细胞|]]